Clinical Trial: Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07852988) titled 'Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes' on Sept. 23.

Brief Summary: Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 c...